NFE2L2 and obesity disorder: Another analog of omaveloxolone, CDDO‐Im, also mildly increased serum cholesterol in an HFD mouse model of obesity, while attenuating weight gain and hepatic fat accumulation and increasing energy expenditure and oxygen consumption.[34] Strikingly, CDDO‐Im did not affect serum cholesterol or produce the profound improvements on obesity in Nrf2‐null mice.